Business Wire

RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product

Share

The Company Received Approval in Multiple European Countries to Initiate this Key Study Necessary for Commercial Product Approval

RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/

RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege.

“The results from this ongoing international multicenter study are exceeding expectations, showcasing remarkable outcomes. We are profoundly optimistic and incredibly enthusiastic about what the future holds,” said Prof. Dr. med. Dent., Patrick Schmidlin, head of the Division of Periodontology at the University of Zurich, who serves as one of the investigators in RevBio’s pivotal clinical trial. “This breakthrough material promises to open a new chapter in dental care, redefining what is possible in regenerative dentistry.”

RevBio received regulatory and ethics committee approvals for five clinical sites consisting of one in Switzerland, two in Belgium, one in Spain, and one in the United Kingdom. Each site is expected to enroll between 12-25 patients for a total of approximately 75 patients. The investigators who are approved to enroll patients in this clinical trial are Prof. Dr. med. Dent., PhD, Patrick Schmidlin, head of the Department of Periodontology at the University of Zurich, Ana Castro, BDS MSc PhD, Clinical Head Department Periodontology at the Catholic University of Leuven, France Lambert, DDS, PhD, Professor and Head of Periodontology, Oral Surgery, and Implant Surgery at the University of Liege, Arturo Llobell, DDS, MS, a periodontist in private practice in Valencia, Spain, and Azim Malik, BDS, MFDS RCSEd, DipPCD RCSI, DClinDent, MPerio RCSEd, a periodontist and implant specialist in private practice in London, United Kingdom.

When teeth are extracted due to damage from traumatic injuries, tooth decay, or gum disease, the current standard of care consists of multiple staged surgical procedures to restore a patient’s dentition with prosthetic crowns supported by dental implants. Frequently, extraction sites are too large for dental implants to achieve primary stability through conventional mechanical engagement. Instead, patients must undergo a costly, complex, and lengthy process including a preliminary bone grafting surgery before receiving a dental implant. The use of TETRANITE to stabilize an unstable implant will allow for the immediate placement of dental implants which otherwise could not be placed until the initial bone graft has healed to form new bone. As a result, the TETRANITE® biomaterial will help reduce the duration and complexity of these dental implant procedures, lessen patient pain and recovery time, and reduce the overall cost of care thereby providing greater patient access for the treatment of tooth loss.

"The approval to conduct this pivotal clinical trial and the successful enrollment of the first 30 patients is a watershed moment for RevBio," said Alan Pollack, DDS, RevBio’s Senior Director of Dental Clinical Operations. “This clinical trial has the potential to significantly accelerate the timeframe when this promising bone adhesive technology can be used in the field of dentistry.”

About RevBio, Inc.

RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of TETRANITE®, a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's TETRANITE technology is not yet approved for commercial use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250306978603/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Group to Announce Full Year 2024 Financial Results on March 28, 202518.3.2025 12:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced that it will report its full year 2024 financial results before the U.S. market open on Friday, March 28, 2025. The Company will hold a conference call on Friday, March 28, 2025 at 8:00 am Eastern Time (or Friday, March 28, 2025 at 9:00 pm Japan Time) to discuss the financial results and take questions live. Please register in advance of the conference using the link provided below. It will automatically direct you to the registration page of "SBC 2024 Full Year Financial Results Briefing". Please follow the steps to enter your registration details, then click "Submit". Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past inve

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression18.3.2025 11:30:00 CET | Press release

Highlights:52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy for a single dose of 25mg lasting about 12 weeks and substantially longer in a subgroupFindings published in the March edition of the Journal of Clinical Psychiatry Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment in patients with treatment-resistant depression (TRD). The COMP004 study's findings suggest that over a 52-week period, a single administration of 25 mg COMP360 psilocybin demonstrated a longer maintenance of antidepressant effects compared to the 1 mg and 10 mg doses. The results of COMP004 build upon previous findings from t

Pole Vault Star Armand “Mondo” Duplantis Sets His Sights on Fairy Tale World Record of 6.40m18.3.2025 11:08:00 CET | Press release

“6.40 metres is achievable in the next few years” Pole vault world-record holder Armand “Mondo” Duplantis believes he can push the pole-vault world record to 6.40 metres in the next few years, the athlete said in a conversation with PUMA CEO Arne Freundt, which was released as a part of the sports company’s annual report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318752992/en/ When it comes to pole vaulting, Mondo is in a league of his own, having won two Olympic gold medals, two world championships, breaking the world record 11 times and being crowned World Athlete of the Year twice. Even though he just set the world record to 6.27 metres earlier this year, the Swedish athlete has his sights on raising the bar to 6.40 metres in the future. “I think that 6.30 metres is probably the target in the near future, and 6.40 metres is achievable in the next few years,” Mondo said. He said improvements in the technology of hi

Pesto Barilla Presents Accademia del Basilico: The New Education Program for Basil Farmers18.3.2025 11:00:00 CET | Press release

As basil sowing begins, Barilla launches Accademia del Basilico, a training program specifically designed to empower farmers and teach techniques and practices for sustainable basil cultivation. With demand for pesto rising globally, the pesto market experienced a 17% growth in volume from 2023 to 2024 1, Barilla places its hero ingredient, basil, at the heart of its sustainability story. Crafted from a 100% Italian basil supply chain, Pesto Barilla is produced with sustainably farmed basil, which is ISCC Plus certified as part of the Barilla Basil Charter, a set of guidelines verified by RINA (independent third party). This concept of sustainability is further strengthened by the new Accademia del Basilico. In collaboration with DINAMICA, an organization specialized in agri-food training with the support of Open Fields Srl, Barilla has developed this comprehensive program, launched in January 2025, consisting of seven lessons aimed at enhancing farming practices across the basil suppl

Res Integra and Ohmium Will Deploy Four-Megawatt Green Hydrogen Project in Sicily18.3.2025 11:00:00 CET | Press release

Advanced PEM Electrolyzers to Decarbonize Petroleum Refinery and Mobility Res Integra is installing an electrolyzer system with an annual capacity of up to 700 tonnes of hydrogen using Ohmium International PEM electrolyzer technology at a facility in an industrial area of Siracusa (Sicily region, Italy), one of the largest petrochemical sites in Europe. The Ohmium green hydrogen PEM solution is targeted for shipment to commence in 2025; the project will be powered by solar PV, producing green hydrogen to support efforts to decarbonize regional industrial operations and mobility. “I’m glad that Res Integra, part of Irem Group, in collaboration with Ohmium International, for the PEM Electrolyzer supply, is realizing this Hydrogen Project. This leads us towards the construction of green energy plants in line with the objectives of the European economic community,” said Giovanni Musso, CEO of Irem. “We sought advanced electrolyzer technology that was efficient, cost-effective, and quick to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye